With a one year PEG ratio of 0.16, Ra Medical Systems Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 3.59% of US stocks.
RMED's went public 1.88 years ago, making it older than merely 3.81% of listed US stocks we're tracking.
In terms of volatility of its share price, RMED is more volatile than 92.66% of stocks we're observing.
Stocks that are quantitatively similar to RMED, based on their financial statements, market capitalization, and price volatility, are CDLX, WBAI, CNET, GHSI, and AACG.
RMED's SEC filings can be seen here. And to visit Ra Medical Systems Inc's official web site, go to www.ramed.com.
RA Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is based in Carlsbad, California.
Ra Medical Systems ([[RMED]] -10.9%) priced public offering of 34.3M shares, along with its accompanying warrants, at $0.35/share; gross proceeds of ~$12M.Warrants, immediately exercisable, have an exercise price of $0.35/share; five years expiry from issuance date.Offering is expected to close on or about August 3, 2020.Proceeds will be used for...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 34,285,714 shares of common stock (or common stock equivalents), together with accompanying warrants to purchase up to an aggregate of 34,285,714 sh
LOS ANGELES--(BUSINESS WIRE)---- $RMED #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED) concerning whether the board breached its fiduciary duty to shareholders. If you are a shareholder, click here for more information. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased Ra Medical securities, have information or would like to learn more about these claims, or ha
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Ra Medical Systems, Inc. (NYSE: RMED).